Electroacupuncture Combined With PD-1 Inhibitor for Elderly Patients With Advanced NSCLC

The goal of this clinical trial is to elucidate the clinical efficacy and safety of electroacupuncture combined with PD-1 inhibitor therapy in elderly patients with advanced non-small cell lung cancer (NSCLC) through a multicenter, randomized controlled clinical trial. The main question it aims to answer is: the combination of electroacupuncture and PD-1 inhibitor therapy has demonstrated significant improvements in both clinical efficacy and safety profiles among elderly patients with advanced NSCLC. Researchers will compare a sham electroacupuncture group combined with PD-1 inhibitor therapy

Trial Details

NCT ID
NCT07086300
Phase
NA
Sponsor
Kong Fanming
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Electroacupuncture (EA)
  • Sham electroacupuncture
Locations (sample)
  • Tianjin, Tianjin Municipality, China|39.14222,117.17667

Key Eligibility Criteria

  • Patients with stage IIIB-IV non-small cell lung cancer (NSCLC) confirmed by histopathological or cytological diagnosis.
  • Patients with negative driver gene mutations, as determined by genetic testing or other molecular biological methods, to exclude common driver muta…
  • Patients aged ≥65 years, with consideration for the patients' overall physical condition. Additional assessments will be conducted if there are com…
  • PD-L1 tumor proportion score (TPS) ≥1%.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →